Highest-materiality recent filing
Amended and restated promissory note with SRX Health Solutions for up to $1,413,600; $663,600 funded on June 23, 2026, on top of $750,000 from May 28 note.
CERo Therapeutics issues $750K convertible note at 10% interest, convertible at $0.05 floor
Issued $750K convertible promissory note ($937.5K face value) to SRX Health Solutions, maturing May 28, 2027.
CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest
Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.
Issued to Keystone Capital Partners a convertible note with purchase price $350,000 and face value $437,500.
Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.
Issued $937,500 convertible note to Keystone Capital Partners at $750,000; 10% interest, matures July 2027, convertible at discount to market.
No cytokine release syndrome (CRS) or ICANS observed despite CD28 costimulatory domain and measurable cell expansion.
Nasdaq Listing Council affirms delisting of CERo Therapeutics securities
On Jan 29, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel's Oct 29, 2025 decision to delist CERo common stock and warrants.
First cohort completed DLT period with no CRS, ICANS, or treatment-related AEs reported.
CERO stockholders approve reverse stock split (1:40–1:150) and 32M share increase to equity plan
Reverse stock split ratio set by board at not less than 1:40 or more than 1:150; approved with 8,012,563 for, 2,287,082 against.
CERO Therapeutics enters new equity line for up to $14.6M from Keystone Capital
Company entered a new Common Stock Purchase Agreement with Keystone Capital for up to $14,591,939 of common stock.
Nasdaq Panel denies CERo Therapeutics continued listing; stock to suspend Oct 31
Shares of CERO common stock will be suspended from Nasdaq at open of trading on October 31, 2025.
CERo Therapeutics closes $2.25M initial closing of Series E preferred stock financing, total $7M
Initial closing of 3,816 Series E preferred shares raised $2.25M gross proceeds on Oct 16, 2025.
CERo Therapeutics raises up to $7M via Series E convertible preferred private placement
Initial closing of ~$1.8M; Series E convertible at $1,000 stated value, conversion price $4.1625 per share.
CERO Therapeutics updates investor presentation with no material new disclosures
Company furnished updated corporate presentation dated September 2025 as Exhibit 99.1, intended for investor meetings.
CERo Therapeutics receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia
FDA granted Fast Track Designation for CER-1236 in AML, adding to existing Orphan Drug Designation.
CERo Therapeutics receives Nasdaq delisting notice for equity shortfall, appeals
Nasdaq staff determined company fails minimum $2.5M stockholders' equity requirement for continued listing.
CERO Therapeutics closes additional $397,600 private placement of Series D Preferred Stock
Issued 497 shares of Series D convertible preferred stock for gross proceeds of approximately $397,600.
CERo Therapeutics enters new common stock purchase agreement for up to $17.5M with Keystone Capital
New Purchase Agreement allows CERo to issue and sell up to $17,490,897 of common stock to Keystone Capital, minus any additional proceeds from prior November deal after June 30, 2025.
CERo Therapeutics regains Nasdaq bid price compliance; delisting hearing canceled
On July 7, 2025, Nasdaq determined CERo regained compliance with the $1.00 minimum bid price rule.
CERo Therapeutics raises $1.85M via Series D preferred stock; adds new institutional investors
Closed additional closing of 2,315 shares of Series D convertible preferred stock for gross proceeds of ~$1,852,000.
FDA grants Orphan Drug Designation to CERo's CER-1236 for AML treatment
FDA Orphan Drug Designation granted to CER-1236 for acute myeloid leukemia (AML).
CERo Therapeutics receives Nasdaq bid price deficiency notice; effects 1-for-20 reverse split
Received Nasdaq notice on June 11, 2025: bid price below $1.00 for 30 consecutive business days (Apr 25–Jun 9).
CERo Therapeutics announces 1-for-20 reverse stock split effective June 13, 2025
Outstanding shares reduced from ~10,321,839 to ~516,092; par value $0.0001 unchanged.
CERo Therapeutics raises ~$750k in Series D financing; first-in-human dosing under way
Gross proceeds from additional closing ~$750k; total Series D up to $8M with $5M previously issued.
CERo Therapeutics enters new employment agreements with CEO and CFO effective June 4, 2025
CEO Chris Ehrlich receives base salary of $480,000/year and a one-time performance bonus of 50% of base salary.
CERO Therapeutics shareholders approve 1:20 reverse stock split, increase share reserve by 2M shares
Reverse stock split ratio set at 1:20, effective 12:01 a.m. ET on June 10, 2025, subject to regulatory processes.
Nasdaq Panel finds CERo Therapeutics again compliant with $2.5M equity rule
On May 7, 2025, Nasdaq Hearings Panel determined CERo complied with Listing Rule 5550(b)(1) (minimum $2.5M stockholders' equity).
CERo files Series D Preferred Stock designation; regains Nasdaq bid price compliance
Filed Certificate of Designations for Series D convertible preferred stock effective April 22, 2025, part of previously reported securities purchase agreement.
CERo raises up to $8M in Series D convertible; believes meets Nasdaq equity requirement
Closed initial $5M of up to $8M Series D convertible preferred; conversion price $0.78, floor $0.156.
CERo Therapeutics regains Nasdaq minimum bid price compliance, moves to Capital Market
Received Nasdaq confirmation of compliance with Bid Price Requirement on Feb 12, 2025.
CERo Therapeutics prices $5M public offering of shares and warrants at $1.96/unit
Offering of 2,551,020 shares and warrants at combined $1.96 price; gross proceeds ~$5M.
CERO Therapeutics gets Nasdaq Panel extension to April 22, 2025 for listing compliance
Nasdaq Panel grants extension to regain compliance with $50M MVLS, $15M MVPHS, and $1.00 bid price requirements.
CERO Therapeutics issues 16.4M shares and warrants upon warrant exercise for $500K
Holder exercised 625 Preferred Warrants at $800/sh, paying $500K (20% OID on $625K stated value).
Cash balance of approximately $5.463 million as of January 7, 2025.
CERo Therapeutics to effect 1-for-100 reverse stock split to cure Nasdaq bid price deficiency
Reverse stock split at 1-for-100 ratio effective Jan 8, 2025; reduces outstanding shares from ~260M to ~2.6M.
CERO Therapeutics issues ~84M new common shares and 8.4M warrants in December capital actions
From Dec 6-26, ~2,600 Series A and 213 Series B preferred shares converted into ~68M common shares.
CERo Therapeutics appoints Chris Ehrlich as permanent CEO
Chris Ehrlich appointed permanent CEO effective Dec 2, 2024, was interim since Oct 2.
FDA clears IND for CER-1236 Phase 1 trial in AML; start expected Q1 2025
FDA cleared CERo's IND for Phase 1 trial of CER-1236 in acute myelogenous leukemia (AML).
Entered into a purchase agreement with Keystone Capital Partners, LLC to sell up to $20,589,384.23 of common stock.
Nasdaq notified CERo on Oct 30, 2024 that it failed to regain compliance with $50M MVLS requirement by Oct 29 cure period.
CERO Therapeutics receives Nasdaq delisting notice; stock price at $0.10 or less
Nasdaq determined to delist CERO common stock due to closing bid price ≤$0.10 for 10 consecutive days.
Submitted complete response to FDA clinical hold on CERO-1236; 30-day review cycle expected.
CERo Therapeutics reports $3.3M preliminary cash; appoints Shami Patel to board
Preliminary unaudited cash and cash equivalents as of Sept 30, 2024 were approximately $3.3 million.
CERo Therapeutics raises ~$1.25M via Series C preferred stock and warrant private placement
Filed Certificate of Designations for Series C Convertible Preferred Stock on Sept 25, 2024.
CERo Therapeutics names new CFO and CDO, reprices options to $0.10
Al Kucharchuk appointed CFO effective Oct 1, 2024; receives 500K stock options vesting over 12 months, monthly consulting fee $16K.
CERo Therapeutics cancels Sep 26 special meeting for reverse stock split, to refile
Special meeting of stockholders scheduled for September 26, 2024, has been canceled.
CERo raises $1.2M, CEO and CTO resign; CER-1236 on clinical hold
CEO Brian Atwood resigns effective no later than Sep 30, 2024; CTO Daniel Corey resigns immediately.
CFO Charles R. Carter to depart CERo Therapeutics; successor search underway
CFO Charles R. Carter informed Board he will leave on Sept 30, 2024 for a role at another public company.
CERo Therapeutics postpones special stockholder meeting to September 26, 2024
Special meeting further postponed from Sept 19 to Sept 26, 2024 at 10:00 a.m. ET.
the Company agreed to employ Mr. Ehrlich as the Company’s Chief Executive Officer as of and from June 4, 2025.
the Company agreed to employ Mr. Kucharchuk as the Company’s Chief Financial Officer as of and from June 4, 2025.
On October 9, 2024, the Board of Directors (the “ Board ”) of the Company appointed Shami Patel to the Board as a Class III director, effective October 11, 2024, to fill the vacancy created by Dr. Corey’s resignation
As previously announced, Charles R. Carter resigned from his position as Chief Financial Officer, effective on September 30, 2024.
On September 30, 2024, the Board appointed Andrew Albert “Al” Kucharchuk as Chief Financial Officer of the Company, effective October 1, 2024.
On September 30, 2024, the Board of Directors (the “ Board ”) of CERo Therapeutics Holdings, Inc. (the “ Company ”) appointed Kristen Pierce, Ph.D., as Chief Development Officer of the Company, effective October 1, 2024.
On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.
On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.
On September 17, 2024, the Chief Financial Officer of CERo Therapeutics Holdings, Inc. (the “ Company ”), Charles R. Carter, informed the Board of Directors of the Company (the “ Board ”) that he expects to accept a new position with another publicly-traded company.
Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof
Max materiality 0.95 · Median 0.65 · Most common event other_material